In November 2004, Bionomics formed a strategic alliance with Genetic Technologies Limited relating to commercialisation of new genetic tests for epilepsy. Under the strategic alliance, Bionomics granted to GTG worldwide testing and marketing rights, including exclusivity for Australia and New Zealand, to new epilepsy tests developed by Bionomics.

The first test to be launched under this programme is a test to identify cases of severe myoclonic epilepsy in infants (SMEI) - a serious form of epilepsy in children. The tests will be performed by GTG and will also be made available to the GENDIA network of international genetic testing laboratories, which will bring these tests to more than 70 countries around the world, including key markets in USA & Europe.

For more information about Genetic Technologies Limited, visit